Quantum-Si outlines Proteus launch in Q2 2027 while lowering 2026 adjusted OpEx guidance to $87M or less (NASDAQ:QSI)

Quantum-Si (QSI) announced the launch of Proteus in Q2 2027 and reduced its 2026 adjusted operating expense guidance to $87M or less. CEO Jeffrey Hawkins highlighted the company's focus on Proteus readiness, launch preparation, and cash preservation, noting that instrument variability issues have been addressed.

Original reporting
Published Nov 6, 2026, 3:16 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 3:21 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$QSI
Bearish
high confidence
Mentioned
$QSI
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$QSIBearishMed
01

Why it matters

Guidance reduction may trigger short‑term price weakness, but long‑term outlook hinges on the Proteus product execution.

02

Market read

Primary company news with new guidance; relevant for traders holding or shorting QSI.

03

What to watch

Potential upcoming product launches (Proteus) may offset cost concerns if successful.

Relevance 6/10Novelty 7/10Timing: post‑earnings call today

Background

Quantum‑Si (NASDAQ:QSI) provided an earnings‑call update, highlighting its 2026 OpEx guidance and upcoming Proteus launch.

Company-level read

Ticker impact

$QSIBearishHigh confidence
Context

Quantum‑Si lowered its 2026 adjusted OpEx guidance to $87M or less, a fresh guidance update disclosed in the earnings call.

Expected impact

downward pressure as investors price in the lower OpEx guidance

Evidence & confidence

The new OpEx target is lower than prior expectations, indicating tighter cash preservation and potential earnings weakness.

Market effects

May signal tighter cost discipline for niche quantum‑sensor firms, affecting peer valuations.

Limited to U.S. micro‑cap segment; no broader regional effect.

Low; the news is company‑specific.

Counterpoint

The OpEx cut could be a sign of disciplined management that preserves cash for future growth, potentially supporting the stock.

Key entities

  • Quantum‑Si

    US‑listed quantum‑sensor developer.

  • Jeffrey Hawkins

    CEO of Quantum‑Si.

Related articles

$QSIMed

Quantum-Si Q3 Earnings Call Highlights

Quantum-Si (QSI) reported Q3 earnings, highlighting progress on its Proteus platform and amino acid detection. The company expects to demonstrate detection of all 20 amino acids by late 2026 and has started a pre-order program. It reduced 2026 expense guidance and maintains sufficient capital for operations until Q4 2028. Supply chain risks are being mitigated. Proteus launch is planned for Q2 2027.

$QSIMed

Quantum-Si Reports Third Quarter 2026 Financial Results and Provides Business Update Proteus™ remains on track for anticipated Q2 2027 commercial launch

Quantum-Si Inc (QSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Quantum-Si Reports Third Quarter 2026 Financial Results and Provides Business Update Proteus ™ remains on track for anticipated Q2 2027 commercial launch BRANFORD, Conn., November 5, 2026 (GLOBE NEWSWIRE) — Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” o

$QSIMed

2 Brain-Computer Interface Stocks to Watch While Neuralink Stays Private

Neuralink, a private brain-computer interface (BCI) company, successfully helped a patient with ALS communicate. Investors cannot buy Neuralink, but two public companies, Quantum-Si (QSI) and Butterfly Network (BFLY), are connected to the BCI field. QSI makes research tools and saw a 7x volume spike, while BFLY supplies ultrasound chips to BCI developers like Merge Labs and Bridge Neurotech.

$QSIMed

Quantum-Si Q2 Earnings Call Highlights

Quantum-Si (NASDAQ:QSI) reported Q2 2026 revenue of $344,000, down from $591,000 a year earlier, and a Q2 net loss of $23.5 million. The company said Proteus launch timing is revised to early 2027, with initial detection of 19 or 20 amino acids. It expects about $12 million annual operating-expense savings and full-year 2026 revenue near $1 million.

$QSIMedAI 8/10

Quantum-Si (QSI) Stock Falls on Q2 2026 Earnings

Quantum-Si Inc. (QSI) reported Q2 2026 revenue of $344,000, above an analyst estimate of $305,020. Diluted EPS was -$0.11, slightly better than expected. The company posted gross profit of $172,000 and an operating loss of $25.6 million, with net loss of $23.5 million. Cash was $23.7 million. Shares fell 1.19% after the release.